CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY
BRACKETS, HAS BEEN OMITTED PURSUANT TO A REQUEST FOR CONFIDENTIAL
TREATMENT PURSUANT TO RULE 24B-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934,
AS AMENDED. THE OMITTED MATERIAL HAS BEEN FILED SEPARATELY WITH THE
SECURITIES AND EXCHANGE COMMISSION.
JOINT DEVELOPMENT AND LICENSING AGREEMENT
This JOINT DEVELOPMENT AND LICENSING AGREEMENT (this “ Development Agreement ”) is
made effective as of the 15th day of May, 2006 (the “ Effective Date ”) by and among ILLUMINA, INC., a
Delaware corporation having its principal place of business at 9885 Towne Centre Drive, San Diego, California,
92121, including its subsidiary CyVera Corporation, having a place of business at 50 Barnes Park North,
Wallingford, CT 06492 (hereinafter collectively referred to as “ Illumina ”), and DECODE GENETICS, EHF., a
limited liability company having its principal place of business at Sturlugata 8, Reykjavik, Iceland (“ deCODE ”).
Illumina and deCODE are sometimes referred to herein individually as a “ Party ” and, collectively, as the “
Parties .” Defined terms have the respective meanings set forth in Section 1 hereof.
1. deCODE possesses certain Intellectual Property, well-phenotyped patient samples, the ability to create
well-planned clinically and statistically relevant cohorts studies in the disease states referred to herein, the ability
to associate research data generated utilizing those cohorts to enable the discovery and validation of potentially
relevant diagnostic content, and has rights to contribute Diagnostic Content.
2. Illumina possesses certain Intellectual Property and has developed a Diagnostic Platform especially
conducive to genotyping multiple SNPs or to assay other relevant diagnostic targets for clinical diagnostics.
3. Illumina has also developed a Discovery Platform that can facilitate extension of the Diagnostic Content to
include other members of the molecular pathways def